Michal Oleksiejczuk Suspended One Year By USADA

Michal Oleksiejczuk was notified of a potential USADA violation from an in-competition sample collected on December 30 of 2017.

It has been announced by USADA that Oleksiejczuk has been suspended one year for the drug testing violation. Since the suspension is retroactive to the date of failure, a suspended Oleksiejczuk is able to fight again on December 30 of this year.

The following statement has been issued by USADA on the matter:

USADA announced today that Michał Oleksiejczuk, of Cyców, Poland, has accepted a one-year sanction for a violation of the UFC Anti-Doping Policy after testing positive for a prohibited substance.

Oleksiejczuk, 23, tested positive for clomiphene following an in-competition urine test conducted on December 30, 2017, at UFC 219 in Las Vegas, Nev. Clomiphene is a Specified Substance in the category of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the WADA Prohibited List.

Oleksiejczuk’s one-year period of ineligibility began on December 30, 2017, the date his positive sample was collected, and is identical in length to the sanction imposed by the Nevada State Athletic Commission (NSAC) on March 13, 2018. In addition, the NSAC overturned Oleksiejczuk’s victory at UFC 219 to a no-contest.

Pursuant to the UFC Anti-Doping Policy, all UFC athletes serving a period of ineligibility for an anti-doping policy violation are required to continue to make themselves available for testing in order to receive credit for time completed under their sanction.

USADA conducts the year-round, independent anti-doping program for all UFC athletes. USADA is an independent, non-profit, non-governmental agency whose sole mission is to preserve the integrity of competition, inspire true sport, and protect the rights of clean athletes. In an effort to aid UFC athletes, as well as their support team members, in understanding the rules applicable to them, USADA provides comprehensive instruction on the UFC Anti-Doping Program website (https://UFC.USADA.org) regarding the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (https://UFC.GlobalDRO.com), conducts educational sessions, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, and periodic athlete alerts.

Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at playclean@usada.org, by phone at 1877-Play Clean (1-877-752-9253), or by mail.

There has been no comment from either Oleksiejczuk or the UFC since the announcement was made by USADA.